ArticleDiscover oncology2026
Two decades of research on drug resistance in renal cell carcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug resistance in renal cell carcinoma (RCC) poses a major challenge to effective treatment. RCC drug resistance is primarily driven by genetic mutations, angiogenesis, immune suppression, metabolic reprogramming, and alternative signaling pathways, which contribute to treatment failure.
objectiveThis study presents a bibliometric analysis of research on drug resistance in renal cell carcinoma (RCC) from 1999 to 2023, aiming to identify key contributors, research hotspots, and future directions.
methodsRelevant literature on renal cancer drug resistance published between 1999 and 2023 was sourced from the Web of Science Core Collection (WoSCC) database. Visual analysis was performed using VOSviewer and CiteSpace software, focusing on contributions from countries, institutions, journals, authors and keywords (such as immune checkpoint inhibitors, ICIs).
resultsA significant increase in research on renal cancer drug resistance has been observed in the past 20 years, based on an analysis of 4130 publications. Harvard University leads in publication output, and Motzer RJ is among the most frequently co-cited authors. The primary research topics include cancer-related clinical trials, drug efficacy assessments, molecular characteristics of tumors, immune microenvironment, and personalized treatment strategies More recent work has focused on understanding the molecular mechanisms behind drug resistance, including the dynamic tumor microenvironment (TME) and metabolic alterations, as well as the role of immune checkpoint inhibitors (ICIs).
conclusionThis bibliometric analysis outlines key trends and research advancements in renal cancer drug resistance over the past two decades. Although there has been substantial progress in comprehensive resistance mechanisms, further research is imperative to elucidate the molecular crosstalk within the TME and therapeutic potential of ICIs in combination with targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.